Godavari Drugs delivered solid financial performance in the quarter ended June 2026, with standalone net profit rising 7% to ₹1.11 crore compared to ₹1.10 crore in the corresponding quarter of the previous year. However, the company faced sequential challenges with profit declining 14% from ₹1.29 crore in Q4FY25. According to the latest financial results, the pharmaceutical company demonstrated consistent year-on-year growth momentum despite operational headwinds during the quarter.
The company's revenue from operations expanded 17% to ₹28.00 crore in Q1 FY2026 compared to ₹23.81 crore in the same quarter of the previous fiscal year. However, material costs surged 45% year-on-year to ₹26.15 crore from ₹17.99 crore, significantly compressing margins and resulting in lower absolute profit figures compared to the strong finish in FY25. This notable divergence between revenue growth and cost structure suggests significant pressure on gross margins, likely due to higher input costs or a shift in product mix towards lower-margin items.
Operating profit margin (OPM) faced significant pressure as the company's total expenses rose to ₹26.93 crore in Q1FY26, up from ₹22.52 crore in Q1FY25. The primary driver of this increase was the surge in material costs, which jumped substantially year-on-year. Despite the revenue growth, the company's ability to maintain profitability was impacted by the substantial increase in input costs, though the company managed to achieve overall net profit growth through effective cost management strategies.
The company completed a significant warrant conversion raising ₹5.25 crore during the quarter, with 7,86,690 warrants converted at ₹89 per share. The allotment was made on a preferential basis to individuals classified under the 'Promoter Category,' increasing the post-allotment paid-up equity share capital from ₹10.13 crore to ₹10.91 crore. Additionally, the company utilized ₹76.33 lakh from its earlier preferential issue for capital expenditure, primarily for manufacturing Active Pharmaceutical Ingredients (APIs) and working capital requirements. The Board of Directors also authorized the allotment of equity shares upon warrant conversion, with the company raising ₹44.12 crore primarily for manufacturing APIs and intermediates.
